State Board of Administration of Florida Retirement System decreased its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) by 19.4% in the 2nd quarter, Holdings Channel reports. The fund owned 12,992 shares of the company’s stock after selling 3,130 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Axsome Therapeutics were worth $498,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. Fairmount Funds Management LLC grew its holdings in Axsome Therapeutics by 402.4% during the 1st quarter. Fairmount Funds Management LLC now owns 942,571 shares of the company’s stock valued at $39,013,000 after purchasing an additional 754,973 shares in the last quarter. US Bancorp DE grew its stake in shares of Axsome Therapeutics by 13,464.6% during the second quarter. US Bancorp DE now owns 262,882 shares of the company’s stock valued at $10,068,000 after acquiring an additional 260,944 shares in the last quarter. Graham Capital Management L.P. increased its position in shares of Axsome Therapeutics by 336.5% during the first quarter. Graham Capital Management L.P. now owns 101,851 shares of the company’s stock worth $4,215,000 after acquiring an additional 78,518 shares during the last quarter. Bellevue Group AG lifted its stake in shares of Axsome Therapeutics by 10.4% in the first quarter. Bellevue Group AG now owns 719,482 shares of the company’s stock worth $29,779,000 after acquiring an additional 67,545 shares in the last quarter. Finally, Endurant Capital Management LP boosted its holdings in Axsome Therapeutics by 80.3% in the first quarter. Endurant Capital Management LP now owns 100,299 shares of the company’s stock valued at $4,151,000 after purchasing an additional 44,670 shares during the last quarter. Hedge funds and other institutional investors own 54.96% of the company’s stock.
Axsome Therapeutics Stock Up 5.5 %
Axsome Therapeutics stock opened at $56.17 on Friday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 4.15 and a current ratio of 4.19. Axsome Therapeutics, Inc. has a one year low of $20.63 and a one year high of $71.98. The company has a 50-day simple moving average of $50.46 and a 200-day simple moving average of $43.25. The firm has a market capitalization of $2.44 billion, a P/E ratio of -13.83 and a beta of 1.75.
Analysts Set New Price Targets
About Axsome Therapeutics
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.
- Get a free copy of the StockNews.com research report on Axsome Therapeutics (AXSM)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.